Jay L Rothstein
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2015First federal award
$12.3MFederal grants as PI15 awards
0Patents grantedNone matched
82Papers4,531 citations
Federal awards and patents by year
AwardsPatents
15 awards · $12.3M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jun 14, 2023 | NIH | SBIR Phase II Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases | $112 | IMMUNEXT, INC. |
| May 20, 2022 | NIH | SBIR Phase II Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases | $975K | IMMUNEXT, INC. |
| Jun 21, 2021 | NIH | SBIR Phase II Immune cell targeting of corticosteroids transforms the treatment of severe, chronic inflammatory diseases | $991K | IMMUNEXT, INC. |
| Jul 31, 2020 | NIH | SBIR Phase II Targeting leukocyte metabolism to treat human autoimmune disease | $996K | IMMUNEXT, INC. |
| Jul 16, 2019 | NIH | SBIR Phase II Targeting the checkpoint regulator VISTA for treatment of inflammatory disease | $1.0M | IMMUNEXT, INC. |
| Jun 26, 2019 | NIH | SBIR Phase II Targeting leukocyte metabolism to treat human autoimmune disease | $996K | IMMUNEXT, INC. |
| Aug 14, 2018 | NIH | SBIR Phase II Targeting leukocyte metabolism to treat human autoimmune disease | $996K | IMMUNEXT, INC. |
| Jul 30, 2018 | NIH | SBIR Phase II Targeting the checkpoint regulator VISTA for treatment of inflammatory disease | $992K | IMMUNEXT, INC. |
| Feb 12, 2018 | NIH | SBIR Phase II Targeting leukocyte metabolism to treat human autoimmune disease | $300K | IMMUNEXT, INC. |
| Aug 7, 2017 | NIH | SBIR Phase II Targeting the checkpoint regulator VISTA for treatment of inflammatory disease | $992K | IMMUNEXT, INC. |
| Apr 27, 2017 | NIH | SBIR Phase II Safe and effective anti CD154 antibodies for therapeutic intervention | $912K | IMMUNEXT, INC. |
| Feb 10, 2017 | NIH | SBIR Phase II Targeting the checkpoint regulator VISTA for treatment of inflammatory disease | $300K | IMMUNEXT, INC. |
| May 9, 2016 | NIH | SBIR Phase II Safe and effective anti CD154 antibodies for therapeutic intervention | $912K | IMMUNEXT, INC. |
| Apr 3, 2015 | NIH | STTR Phase II Validation of a Negative Regulator as a Novel Therapy for Autoimmune Disease | $954K | IMMUNEXT, INC. |
| Feb 27, 2015 | NIH | SBIR Phase II Safe and effective anti CD154 antibodies for therapeutic intervention | $1.0M | IMMUNEXT, INC. |
1 patents as inventor
- US IMMUNEXT, INC.—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#37
Awards as PI#46
Patents#273
Companies
- IMMUNEXT, INC.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.